

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Innovent

信達生物製藥

INNOVENT BIOLOGICS, INC.

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 1801)

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF BOARD COMMITTEES

This announcement is made pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The board (the “**Board**”) of directors (the “**Directors**”, each a “**Director**”) of Innovent Biologics, Inc. (the “**Company**”) hereby announces that Dr. Kaixian Chen (“**Dr. Chen**”) has tendered his resignation as an independent non-executive Director to dedicate time to his other professional commitments, with effect from December 27, 2024. Upon Dr. Chen’s resignation, Dr. Chen also resigned from his role as a member of each of the remuneration committee of the Board (the “**Remuneration Committee**”), the audit committee of the Board and the nomination committee of the Board.

Dr. Chen has confirmed that (i) he has no claim against the Company in respect of his resignation and there is no disagreement between him and the Board; and (ii) there are no matters that need to be brought to the attention of the Stock Exchange and the shareholders of the Company in relation to his resignation.

The Board would like to take this opportunity to express its sincere gratitude to Dr. Chen for his valuable contribution to the Company during his tenure of office as an independent non-executive Director and a member of each of the Remuneration Committee, the audit committee and the nomination committee.

Mr. Gary Zieziula, an independent non-executive Director, has been appointed as a member of the Remuneration Committee, with effect from December 27, 2024.

By order of the Board
Innovent Biologics, Inc.
Dr. De-Chao Michael Yu
Chairman and Executive Director

Hong Kong, China, December 27, 2024

As at the date of this announcement and following the above resignation of Director, the Board comprises Dr. De-Chao Michael Yu as Chairman and Executive Director and Mr. Ronald Hao Xi Ede and Ms. Qian Zhang as Executive Directors, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Mr. Gary Zieziula, Dr. Shun Lu and Mr. Shuyun Chen as independent Non-executive Directors.